Is CHE a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for CHE (CHE) rests on VITAS hospice demand and aging demographics: An aging US population and rising acceptance of hospice care support steady demand for VITAS services. Revenue (TTM) is ~$2.5B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: VITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. Whether CHE is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Chemed Corporation runs two entirely unrelated businesses under one holding company. VITAS Healthcare, roughly two-thirds of revenue, is a leading provider of end-of-life hospice and palliative care, drawing well over 90% of its revenue from Medicare and Medicaid per-diem payments. Roto-Rooter, the remaining third, is the largest US provider of plumbing, drain cleaning, and water-damage restoration, serving both residential and commercial customers through company-owned operations and franchises. The two segments share little operationally but together produce steady consolidated cash flow that management returns via buybacks and a small dividend. The investment picture is one of slow, reliable compounding rather than rapid growth. VITAS benefits from aging demographics and rising hospice utilization but is capped by Medicare per-patient limits and tight regulatory oversight, while Roto-Rooter is more cyclical and weather-sensitive, and has recently seen softer demand and margin pressure in its restoration business. In early 2026 VITAS was the stronger performer (revenue up around 3%) while Roto-Rooter revenue dipped slightly, and management raised full-year adjusted EPS guidance. Investors weigh a defensive, high-return-on-capital model against reimbursement risk, plumbing cyclicality, and a valuation that already reflects the company's quality.
What's the case for buying CHE?
1. VITAS hospice demand and aging demographics
An aging US population and rising acceptance of hospice care support steady demand for VITAS services. VITAS grew net revenue roughly 3% year over year in Q1 2026 to about $420 million, and management has been expanding capacity and admissions. Because hospice is a defensive, non-discretionary service, this segment provides ballast against economic cycles.
2. Reduced Medicare Cap drag
VITAS has periodically faced Medicare Cap billing limitations that force refunds when payments exceed per-patient ceilings. Management projected the Cap headwind to fall sharply to roughly $9.5 million in 2026 from about $27.2 million in 2025, which supports higher realized VITAS revenue and margins if admissions and length-of-stay trends hold.
3. Roto-Rooter footprint and franchise buy-ins
Roto-Rooter is the dominant national brand in plumbing and drain services, giving it pricing power and brand recall competitors lack. Chemed continues to buy back independent franchise territories (adding markets serving millions of people in early 2026), converting franchise royalties into higher-margin company-owned revenue over time.
4. Strong cash generation and buybacks
Chemed converts earnings into substantial free cash flow (roughly $325 million after capex in 2025) with low debt, and consistently repurchases shares. This capital-return discipline steadily shrinks the share count and supports per-share earnings even when consolidated revenue grows only in the mid-single digits.
What are the risks to CHE?
VITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. The hospice industry faces heavy regulatory oversight (Conditions of Participation, anti-kickback and false-claims rules, audits, and past MAC repayment demands), and VITAS disclosed a 2025 cyberattack exposing protected health information. Roto-Rooter is cyclical and weather-dependent, with recent softness in restoration demand and margin pressure, plus reliance on scarce licensed-plumber labor. The stock also trades at a premium multiple, so any disappointment on volumes or margins can drive sharp drawdowns, as seen after weaker quarters.
How is CHE valued? (as of July 2026)
Snapshot for CHE as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$2.5B
- Net income (FY2025): ~$265M
- Free cash flow (FY2025, after capex): ~$325M
- 2026 adjusted EPS guidance: ~$23.25-$24.25
- Market cap: ~$6B
- P/E ratio: ~20x
Chemed posted 2025 revenue of about $2.53 billion (up ~4%) with net income near $265 million, and Q1 2026 consolidated revenue of roughly $657 million split about $420 million VITAS and $237 million Roto-Rooter. The stock traded near $480 in early July 2026, giving a market cap around $6 billion and a trailing P/E in the low-20s. Management raised full-year 2026 adjusted EPS guidance to roughly $23.25 to $24.25.
How do you decide if CHE is a buy?
Rather than asking whether CHE is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CHE indirectly through an index or sector ETF before adding more.
For the full picture, see the CHE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CHE against your real portfolio and see your actual exposure before deciding.
The bottom line on CHE
The bottom line: CHE's story right now is VITAS hospice demand and aging demographics, with revenue (ttm) at ~$2.5B. If you believe that narrative continues, the call is about sizing CHE sensibly and checking overlap with what you own; if you doubt it (the risk: vITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around CHE with Walnut
Use CHE as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CHE a good stock to buy right now?
+
The case for CHE right now is VITAS hospice demand and aging demographics, with revenue (ttm) at ~$2.5B. If you believe that thesis holds, CHE is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is vITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does CHE do?
+
Chemed Corporation runs two entirely unrelated businesses under one holding company.
What are the main risks of CHE?
+
VITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results. The hospice industry faces heavy regulatory oversight (Conditions of Participation, anti-kickback and false-claims rules, audits, and past MAC repayment demands), and VITAS disclosed a 2025 cyberattack exposing protected health information. Roto-Rooter is cyclical and weather-dependent, with recent softness in restoration demand and margin pressure, plus reliance on scarce licensed-plumber labor. The stock also trades at a premium multiple, so any disappointment on volumes or margins can drive sharp drawdowns, as seen after weaker quarters.
What does Chemed Corporation do?
+
Chemed operates two unrelated businesses: VITAS Healthcare, a large US hospice and palliative-care provider, and Roto-Rooter, the biggest North American plumbing, drain-cleaning, and water-restoration brand. VITAS is roughly two-thirds of revenue and Roto-Rooter the remaining third.
How does Chemed make money?
+
VITAS earns per-diem payments, mostly from Medicare and Medicaid, for caring for terminally ill patients. Roto-Rooter earns service fees from residential and commercial plumbing, drain, and restoration jobs plus royalties from independent franchise territories.
Why are hospice and plumbing in the same company?
+
It is a legacy conglomerate structure. The two segments share little operationally but both generate steady cash flow, and Chemed manages them in a decentralized way while allocating the combined cash toward buybacks, franchise acquisitions, and a modest dividend.
What are the biggest risks for CHE?
+
The largest is VITAS's heavy dependence on Medicare and Medicaid reimbursement, including the annual per-patient Medicare Cap and strict regulatory audits. Other risks include Roto-Rooter's cyclicality and labor needs, cybersecurity exposure, and a premium valuation that can amplify drawdowns after weak quarters.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CHE; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.